NCT05737199 is a Phase 2 clinical trial of MK-3475 (pembrolizumab) in Ovarian Squamous Cell Carcinoma, sponsored by Niigata University Medical & Dental Hospital.

Who is sponsoring NCT05737199?

NCT05737199 is sponsored by Niigata University Medical & Dental Hospital.

What drugs are being tested in NCT05737199?

Interventions in NCT05737199: MK-3475 (pembrolizumab).

What condition does NCT05737199 study?

NCT05737199 studies Ovarian Squamous Cell Carcinoma.

Is NCT05737199 still recruiting?

NCT05737199 is currently active, enrolled. Last updated 5 February 2026.

Last reviewed 2026-02-05 · How we verify

NCT05737199

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Assessment of the Efficacy and Safety of Pembrolizumab for Ovarian Squamous Cell Carcinoma

Active, enrolled Phase 2 Last updated 5 February 2026

What this trial tests

Phase 2 trial testing MK-3475 (pembrolizumab) in Ovarian Squamous Cell Carcinoma in 21 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 May 2023

Primary endpoint
31 May 2028

31 May 2028

Quick facts

Lead sponsor	Niigata University Medical & Dental Hospital
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	21
Start date	1 May 2023
Primary completion	31 May 2028
Estimated completion	31 May 2028
Sites	1 location across Japan

Drugs / interventions tested

MK-3475 (pembrolizumab) — full drug profile →

Conditions studied

Ovarian Squamous Cell Carcinoma — all drugs for Ovarian Squamous Cell Carcinoma →

Sponsor

Niigata University Medical & Dental Hospital

Who can join

18 and older, female only, with Ovarian Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase II, non-randomized, open-label, single-arm, multicenter study to evaluate the efficacy and safety of MK-3475 in patients with ovarian squamous cell carcinoma.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

An Attempt to Develop a New Treatment Strategy for Rare Refractory Gynecological Malignancies: The Japanese Gynecologic Oncology Group.
Shigeta S, Shimada M, Suzuki S, Kajiyama H, et al · · 2023 · cited 2× · PMID 37941704 · DOI 10.31662/jmaj.2023-0024
Refractory ovarian squamous cell carcinoma arising from a seromucinous borderline tumor with squamous overgrowth: A case report.
Tamura R, Kushiya N, Yamaguchi M, Nishikawa N, et al · · 2024 · PMID 38273936 · DOI 10.1016/j.gore.2024.101323

Verify or expand the search:

Other recruiting trials for Ovarian Squamous Cell Carcinoma

Currently open trials in the same condition.

NCT02834013 — Nivolumab and Ipilimumab in Treating Patients With Rare Tumors · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05737199 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Niigata University Medical & Dental Hospital
Last refreshed: 5 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05737199.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing